{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:53:33Z","timestamp":1795107213522,"version":"4.10.3"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ygyno.2021.12.031","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T14:05:08Z","timestamp":1642601108000},"page":"481-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study"],"prefix":"10.1016","volume":"164","author":[{"given":"Brian M.","family":"Slomovitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia L.","family":"Filiaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Moroney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee C.","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.12.031_bb0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2021.12.031_bb0010","series-title":"Uterine Cancer","author":"SEER Cancer Stat Facts","year":"2018"},{"issue":"1","key":"10.1016\/j.ygyno.2021.12.031_bb0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","article-title":"Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study","volume":"40","author":"Morrow","year":"1991","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.12.031_bb0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ygyno.2012.03.034","article-title":"Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study","volume":"125","author":"Miller","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"7447","key":"10.1016\/j.ygyno.2021.12.031_bb0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"The Cancer genome atlas research N. integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2021.12.031_bb0030","series-title":"Integrated genomic characterization of endometrial carcinoma. Nature","first-page":"67","article-title":"The cancer genome atlas research N","volume":"497","author":"Levine","year":"2013"},{"issue":"21","key":"10.1016\/j.ygyno.2021.12.031_bb0035","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"S0090\u20138258(18)","key":"10.1016\/j.ygyno.2021.12.031_bb0040","article-title":"Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: a NCI clinical trials planning meeting report","volume":"18","author":"Lheureux","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.12.031_bb0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cncr.28414","article-title":"Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer","volume":"120","author":"Mackay","year":"2014","journal-title":"Cancer."},{"issue":"8","key":"10.1016\/j.ygyno.2021.12.031_bb0050","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2021.12.031_bb0055","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/sim.2139","article-title":"One-and two-stage designs for stratified phase II clinical trials","volume":"24","author":"London","year":"2005","journal-title":"Stat. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2021.12.031_bb0060","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer."},{"issue":"9","key":"10.1016\/j.ygyno.2021.12.031_bb0065","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/bjc.2013.183","article-title":"Everolimus as second-or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO","volume":"108","author":"Ray-Coquard","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.12.031_bb0070","series-title":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)","first-page":"1095","author":"Emons","year":"2016"},{"issue":"24","key":"10.1016\/j.ygyno.2021.12.031_bb0075","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group","volume":"29","author":"Oza","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.12.031_bb0080","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2013.59","article-title":"Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial","volume":"108","author":"Colombo","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2021.12.031_bb0085","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1200\/jco.2011.29.15_suppl.5013","article-title":"Phase II study of oral ridaforolimus in patients with metastatic and\/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192","volume":"29","author":"Mackay","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.12.031_bb0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.12.031_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.12.031_bb0100","first-page":"170","article-title":"Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines","volume":"16","author":"Koh","year":"2018","journal-title":"Oncology."},{"key":"10.1016\/j.ygyno.2021.12.031_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.10.003","article-title":"Targeting mTOR pathway in gynecological malignancies: biological rationale and systematic review of published data","volume":"108","author":"Kassem","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.12.031_bb0110","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2014.06.033","article-title":"Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer","volume":"135","author":"Tsoref","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"31","key":"10.1016\/j.ygyno.2021.12.031_bb0115","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2014.58.8871","article-title":"Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma","volume":"33","author":"Oza","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.12.031_bb0120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.12.031_bb0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2016.04.019","article-title":"A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer","volume":"142","author":"del Campo","year":"2016","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821016991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821016991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:30Z","timestamp":1758772710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821016991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0090825821016991"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.031","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}